Kevin is the Jan Fandrianto and Selfia Halim Distinguished Professor in Engineering at the University of California at Berkeley. He is a thought leader and innovator working at the interface between stem cells and materials science to develop dynamic engineered systems to explore new applications in translational medicine. He is an elected Fellow of AIMBE, AAAS, FBSE, BMES. Kevin has extensive experience in managing large R&D programs, and has launched numerous startups.
Samuel T. Wall, PhD
Sam has a background in medical device development, biomaterials, and stem cell science, and an additional 12 years of academic experience in scientific software and computational systems related to the cardiovascular system. He has multiple patents and is focused on industrial applications of modern computational systems, specifically the use of data augmented modeling and data assimilation for personalized mechanistic modeling.
Mark Warren, PhD
Senior Research Scientist
Mark has worked extensively in the cardiac arrhythmia field. After graduating in Physics, his interests in superconducting materials rapidly shifted to cardiac disease, and to how the altered conductivity of infarcted tissue triggered deadly arrhythmia during a heart attack. Mark's research into the mechanisms of cardiac arrhythmia has been published in various high impact journals. He now strives to apply his skills and experience to improving drug screening at Organos.
Brian completed an internship from the California Institute of Regenerative Medicine, acquiring extensive experience in the culture and differentiation of human induced pluripotent stem cells. He succeeded in generating high quality and efficiently pure cardiomyocytes from numerous patient-specific cell lines at the University of California, Berkeley, aiding in the progression of the heart-on-a-chip model for the advancement of drug screening and understanding of complex heart diseases.
Abhishek is a MBA/Masters in Public Health candidate at UC Berkeley Haas School of Business, where he is focusing on how AI/ML can be used to revamp drug discovery for novel therapeutics. Previously, he worked at Deloitte Consulting for four years, where he advised biotech/pharma Fortune 500 companies and startups on business model design, supply chain strategy and digital transformation through various SaaS tools. At Organos, he focuses on core product and go-to-market strategy, financial modeling and partnership development with the desire to decrease the time-to-market for drugs and improve affordability for patients.